vialaudit

affiliate disclosure · we earn commission on some vendor links. audits, scores, and rankings are independent — vendors do not pay for placement. read more →

NEWS · 9 MIN·UPDATED 2026-11-12·BY ELI WHITMER

CJC-1295 + ipamorelin: what 69 lab results show

69 public CJC-1295 + ipamorelin blend results: median fill 111.5% of label, lowest 101.2%, purity 99.79%, no fails. Plus FDA's compounding votes.

QUICK ANSWER

CJC-1295 + ipamorelin is a two-peptide research vial: a modified GHRH analogue (on these certificates, always the version without DAC) mixed with the ghrelin-receptor agonist ipamorelin. Neither peptide has FDA approval, and FDA's compounding advisers voted against both: ipamorelin 0 to 12 on 29 October 2024 and every CJC-1295 form on 4 December 2024. On the public lab record the vials test well. Across 69 results from 54 clients, no result was graded a fail, median purity was 99.79%, and the median vial held 111.5% of its label. None of the 62 blend totals came in under label; the lowest was 101.2%. The certificates cover quantity, identity and purity. Two in three carry an endotoxin line and about half a sterility screen. We tested none of these vials ourselves.

The CJC-1295 + ipamorelin blend is one of the most-tested vials on the public record, and it tests well: 69 results from 54 clients, 0 graded a fail, median purity 99.79%, median fill 111.5% of label. Not one of 62 blend totals came in under label. These are results that vendors and labs chose to publish, not a random sample of what is sold. Neither peptide has FDA approval, and FDA's compounding advisers voted against both in late 2024.

The blend at a glance.

What it isCJC-1295 without DAC (modified GRF 1-29) plus ipamorelin, in one vial
Most common label10 mg total (all 60 Kovera results)
Lab results we mirror69, from 3 labs, 54 client names
Test dates31 Jul 2025 to 10 Jun 2026
Median fill, blend total111.5% of label (62 results)
Lowest / highest fill101.2% / 213.5%
Under label0 of 62
Median purity99.79% (63 results), lowest 98.23%
Graded fail / identity failed0 / 0
Carry an endotoxin result45 of 69
Carry a sterility screen33 of 69
US approvalNone, for either peptide
503A compoundingAdvisory committee voted against: ipamorelin 29 Oct 2024, CJC-1295 4 Dec 2024
HHS policy, 28 Oct 2026Neither among the six peptides covered

Sources for each row are in the sections below.

What is in the vial.

CJC-1295 without DAC. Also sold as modified GRF 1-29; unmodified GRF 1-29 is sermorelin. FDA's briefing document for the December 2024 meeting describes the CJC-1295 core as human GHRH 1-29 with four amino acids swapped, at positions 2, 8, 15 and 27. The "DAC" (drug affinity complex) form adds a maleimide-bearing lysine that binds to albumin in the blood. In healthy adults given the DAC form, the mean estimated half-life ranged from 5.4 to 9.2 days. FDA found no nonclinical studies establishing whether the form without DAC is pharmacologically active (FDA briefing, CJC-1295). Our CJC-1295 guide covers both forms.

Ipamorelin. A pentapeptide agonist of the ghrelin receptor (GHSR), described in 1998 as the first secretagogue in its class to raise growth hormone in animals without a matching rise in adrenocorticotropic hormone (ACTH) or cortisol (Raun et al., European Journal of Endocrinology, 1998). Our ipamorelin guide has the background, and our CJC-1295 vs ipamorelin piece explains why sellers pair them.

What the certificates call it. Every certificate in the pool that names the CJC form names the one without DAC. 57 of 60 Kovera certificates read "CJC-1295 (No DAC)/Ipamorelin"; three print a shorter name. All six Janoshik reports and all three Ascension certificates say "no DAC", "without DAC" or "mod GRF 1-29". There is no DAC blend in the record. A seller listing a DAC blend is selling something no certificate here covers.

We make no claim about what either peptide does in people.

The US regulatory record.

DateEventSource
29 Oct 2024Pharmacy Compounding Advisory Committee votes against adding ipamorelin to the 503A bulks list: free base 0 yes, 12 no, 1 abstain; acetate the sameFinal summary minutes, 29 Oct 2024
4 Dec 2024Committee votes against all five CJC-1295 forms: free base 0 to 13, acetate 1 to 12, each DAC form 0 to 13Final summary minutes, 4 Dec 2024
22 Apr 2026FDA safety-risk page lists CJC-1295 and ipamorelin acetate under "nominated but withdrawn"; ipamorelin acetate stays in Category 2 under the 503B interim policyFDA Category 2 page
28 Oct 2026HHS files its 503A peptide enforcement-discretion policy; neither peptide is among the sixFederal Register doc 2026-22192

The votes. The 503A bulks list names the bulk substances that pharmacies compounding under section 503A may use. In both meetings the committee first voted 12 to 1 to take the forms together; because one member said no, FDA took separate votes on each. For ipamorelin, the minutes record members citing a lack of information supporting safety and efficacy for the two uses nominated, growth hormone deficiency and postoperative ileus. For CJC-1295, the free-base vote was unanimous, with one member commenting on the lack of evidence for effectiveness.

The safety-risk page. As of 22 April 2026, FDA's risk notes for CJC-1295 say compounded drugs containing it "may pose risk for immunogenicity" and that FDA "has identified serious adverse events", including increased heart rate and a systemic vasodilatory reaction. For ipamorelin acetate under 503B, FDA cites a published study reporting serious adverse events, including death, when it was given intravenously. FDA's CJC-1295 briefing also cites anecdotal reports that a participant in a 2006 HIV lipodystrophy study of the DAC form died, a death the attending physician attributed to coronary artery disease. Moving off Category 2 for 503A does not make either peptide eligible: neither is on the 503A bulks list.

The HHS policy. The HHS policy text covers six peptides in Appendix A: BPC-157, TB-500, epitalon, KPV, MOTS-c and semax. CJC-1295 and ipamorelin are not among them. Our HHS policy explainer covers the conditions.

Neither is a controlled substance, and federal law does not make possessing them a crime. Selling either for human use is selling an unapproved drug. Both are named under S2.2.4 of the WADA 2026 prohibited list. Our peptide legality tool keeps the record for CJC-1295 with and without DAC and for ipamorelin.

What 69 public lab results show.

We pooled blend results from the six certificate sources in our 2,087-result purity study, with the same rules for duplicates. Four sources carried the blend; Particle Peptides and Swiss Chems had none. We left out triple blends that add tesamorelin, and one Janoshik catalogue entry with no readable result.

SourceResultsWhat it reportsMedian fillMedian purityTest dates
Kovera Labs public verifier60Blend total, per-component split on 51, purity, identity111.5%99.79%Feb to May 2026
Janoshik public tests5Per-component amounts, identitysee belownot reportedNov 2025 to Jun 2026
Injectify test reports (Janoshik)1Per-component amounts, identitysee belownot reportedJan 2026
Ascension Peptides COA page (MZ Biolabs)3Per-component amounts on 2, purity115.4%, 119.6%99.71%Jul 2025 to Mar 2026
All sources69111.5% (62 totals)99.79% (63)Jul 2025 to Jun 2026

The pool carries 54 distinct client names. Our October study counted 68 blend results and 53 clients; the small difference comes from how blend names are matched across sources. The median fill, median purity and fail count are the same.

Fill: how much is in the vial.

Fill band, blend totalResultsShare of 62
Under 100% of label00%
100% to 105%34.8%
105% to 110%1524.2%
110% to 115%3150.0%
115% to 120%1219.4%
Over 120%11.6%

The middle half of results sits between 109.0% and 114.8% of label. Across all fill results in the wider study the median was 109.6%; the blend runs a little higher.

The three lowest are Kovera certificates for 10 mg vials, all still over label: client GMR Compounds at 10.12 mg (KVR-2026-AEBCF8, 20 May 2026), Mile High Compounds at 10.36 mg (KVR-2026-C194BA) and Orbitrex Peptides at 10.40 mg (KVR-2026-4CFDF3).

The outlier is client Atomik Labz: 21.35 mg in a vial labelled 10 mg, or 213.5%, with 10.79 mg of CJC-1295 and 10.56 mg of ipamorelin (KVR-2026-EA528D, analysed 9 May 2026). That is twice the content of every other 10 mg vial in the pool, which points to a 20 mg fill under a 10 mg label. The certificate prints a net-content specification of "10mg ± 10%" and marks the result a pass, as served when we re-read it on 10 November 2026. It is not alone: as served on 10 November, 37 Kovera blend certificates print that specification, measure more than 11 mg, and mark net content a pass. Three more did until Kovera re-issued them with a "~10mg" specification. Overfill leaves no peptide missing, but the label no longer states the amount in the vial.

Per component: how the 10 mg splits.

A blend total can hide a short component. 51 Kovera certificates, as served on 10 November 2026, break the total into its two peptides. Leaving out the 21.35 mg outlier, the other 50 show:

ComponentMedianRange
CJC-1295 (no DAC)5.59 mg5.11 to 5.98 mg
Ipamorelin5.57 mg4.96 to 6.24 mg

Kovera prints no per-component label, so these are amounts, not fill percentages. The ratio of ipamorelin to CJC-1295 sat between 0.89 and 1.12 on every one.

The Janoshik-tested reports do print a label per component:

ReportLabel (CJC / ipa)CJC-1295 measuredIpamorelin measuredAnalysed
Janoshik #894045 / 5 mg6.24 mg (124.8%)5.13 mg (102.6%)20 Nov 2025
Janoshik #968464 / 4 mg4.44 mg (111.0%)4.01 mg (100.3%)7 Jan 2026
Injectify's copy of Janoshik #97330 (report)5 / 5 mg5.28 mg (105.6%)4.31 mg (86.2%), as we read it8 Jan 2026
Janoshik #1218345 / 5 mg7.27 mg (145.4%)5.97 mg (119.4%)17 Mar 2026
Janoshik #171938, two vials10 / 10 mg10.91 and 10.53 mg10.47 and 10.12 mg10 Jun 2026

A sixth Janoshik report (#155067, 14 May 2026) measured 5.37 mg of CJC-1295 and 5.96 mg of ipamorelin with no label printed. The Injectify copy of report #97330 is the only result in the record with a component under its label; the ipamorelin figure is our reading of that report. Ascension's two quantified FIT Stack certificates (MZ Biolabs, 10 February and 20 March 2026) measured 10.35 and 10.77 mg of CJC-1295 with 12.73 and 13.14 mg of ipamorelin in 20 mg vials.

Purity.

Purity here is the HPLC (high-performance liquid chromatography) figure the certificate prints.

Purity bandResultsShare of 63
99.5% or higher5892.1%
99% to 99.5%34.8%
98% to 99%23.2%
Under 98%00%

The lowest is client Empowher Premium Labs at 98.23% (KVR-2026-C8ADFC, 27 May 2026), above the ">98%" specification Kovera prints. The other result under 99% is Kovera certificate KVR-2026-70B51D: its certificate as we extracted it gives 98.97%, while the average result line Kovera now serves reads 99.010%. On the 51 certificates with a split, each component's own purity had a median of 99.80% (CJC-1295) and 99.78% (ipamorelin). Janoshik and Injectify reports for this blend print no purity figure, so the 63 are Kovera and Ascension results.

Fails and identity.

No result in the 69 was graded a fail, and every certificate that reports identity confirmed both peptides. Kovera and Ascension grade their results; Janoshik's blend reports carry amounts without a pass or fail grade, so for those "no fail" means no failed identity, not a graded pass.

Endotoxin and sterility.

TestCertificates carrying itResult
Endotoxin45 of 69 (all Kovera)All pass against "≤0.5 EU/mL" (endotoxin units per millilitre); 36 records give the result as under 0.10 EU/mL
Microbial sterility screen33 of 69 (all Kovera)All "No Growth"; Kovera labels 30 of them a rapid sterility test
Heavy metals32 of 69 (all Kovera)All reported negative or below a stated limit

The other 24 results, every Janoshik, Injectify and Ascension certificate and 15 Kovera ones, carry none of these. An endotoxin limit per millilitre also depends on how much liquid the lab dissolved the sample in; our endotoxin guide works through what a figure means per vial.

Re-issued certificates.

Four Kovera blend certificates have been re-published since August 2026 with their net-content specification changed from "10mg ± 10%" to "~10mg": KVR-2026-A04CA6 (7 August) and three on 3 November. Those three also had the product name shortened, to "CJC/Ipa", "CJC + Ipa" and a version ending "10MG". The purity figures did not change, and one net content moved by 0.01 mg (11.35 to 11.36 mg, KVR-2026-C19AC4). Our re-issued certificates report tracks the pattern.

The bias you have to read first.

Every result here is one that a vendor or buyer chose to send to a lab, and one the lab or vendor chose to publish. Kovera and Janoshik publish fails next to passes, but the client still decides which vials reach them, and a vendor with a bad certificate can leave it off its own page. Zero fails in 69 is a statement about the published record, not a failure rate for the blend on the market.

The record is also concentrated: 60 of 69 results are Kovera certificates from a 15-week window in 2026. One result moves the fill median by a fraction of a point. Read the tables as a description of 69 certificates, not a forecast for the next vial.

What a buyer can and cannot conclude.

You can concludeYou cannot conclude
Published blend vials on this record held at least their labelled totalThat a vial you buy holds its label
Purity by HPLC was above 98% on every result with a figureThat the vial is free of endotoxin or microbes, unless its own certificate shows those tests
The CJC-1295 on these certificates is the no-DAC formThat a "DAC" blend has ever been tested on the public record
Kovera's 10 mg blends split close to evenly between the two peptidesThat a Janoshik blend report's total equals the label: read each component
Kovera marked 37 over-spec fills a pass (as served 10 Nov 2026)That a "pass" on net content means the amount is close to label

Prices.

Our price index holds no CJC-1295 + ipamorelin blend listing in its build of 10 November 2026, so we publish no price per mg for it. The index tracks single-peptide CJC-1295 at one vendor.

How to read a CJC-1295 + ipamorelin certificate.

  1. Check the CJC form. The certificate should say no DAC, without DAC or mod GRF 1-29, and match what the listing sold.
  2. Read both components. A blend total can be on label while one peptide is short. Look for a per-component amount and, where printed, a per-component label.
  3. Read the specification next to the result. A "pass" against "10mg ± 10%" with 11.8 mg measured tells you the grade does not follow the printed specification.
  4. Look for the panels that are not there. Endotoxin and sterility are separate tests. A third of the certificates here carry no endotoxin result.
  5. Verify at the lab and match the lot. Use Kovera's verifier or Janoshik's, and our guides to verifying a peptide COA and verifying a Janoshik COA. A certificate covers one tested sample.

Our methodology page explains how we read and score lab records.

What we read, and what we did not.

We read 69 blend certificates in our mirrors of Kovera Labs' public verifier (re-read 10 November 2026), Janoshik's public test listing (30 June 2026), Injectify's test reports (May 2026) and Ascension Peptides' certificate pages (May 2026). We read FDA's briefing document on CJC-1295 for the 4 December 2024 meeting, the final summary minutes of the 29 October and 4 December 2024 meetings, FDA's safety-risk page (current as of 22 April 2026) and the Federal Register notice 2026-22192. The list of six peptides is from Appendix A of the HHS policy text. We did not test any vial, and we do not publish the client email addresses printed on some certificates.

Sources.

Frequently asked

What is the CJC-1295 and ipamorelin blend?

One vial holding two peptides. CJC-1295 without DAC (also called modified GRF 1-29) is a 29-amino-acid analogue of growth hormone-releasing hormone with four amino acids substituted. Ipamorelin is a five-amino-acid agonist of the ghrelin receptor. Sellers most often label the blend 10 mg in total.

Is the CJC-1295 in these blends with or without DAC?

Without DAC, on every certificate that says. 57 of the 60 Kovera certificates name "CJC-1295 (No DAC)"; the other three now print only "CJC/Ipa", "CJC + Ipa" or "CJC/Ipamorelin". Every Janoshik and Ascension certificate names the no-DAC form. None of the 69 results is a DAC blend.

Are CJC-1295 ipamorelin blends underfilled?

Not on the published record. Of 62 results that give a measured total against a labelled total, none was under label. The lowest was 10.12 mg in a 10 mg vial (101.2%) and the median 111.5%. One single component is under its own label on the record: as we read Injectify's published copy of Janoshik report #97330 (analysed 8 January 2026), it lists 4.31 mg of ipamorelin against a 5 mg label.

How pure are CJC-1295 ipamorelin vials on the public record?

Across 63 results with a purity figure, median HPLC purity was 99.79%. Two were under 99% and none under 98%; the lowest was 98.23%. Janoshik's reports for this blend print amounts and identity but no purity figure.

Do these certificates test for endotoxin or sterility?

Some do. 45 of the 69 carry an endotoxin result and 33 a microbial sterility screen, all of them Kovera certificates, all passes. Janoshik, Injectify and Ascension certificates for the blend report neither. Purity and fill say nothing about either.

Is CJC-1295 with ipamorelin FDA approved or compoundable?

Neither. Neither peptide has FDA approval. FDA's Pharmacy Compounding Advisory Committee voted against adding ipamorelin to the 503A bulks list on 29 October 2024 and against every CJC-1295 form on 4 December 2024. Neither is among the six peptides in the HHS compounding policy filed on 28 October 2026.

Is CJC-1295 ipamorelin legal to buy in the US?

Neither peptide is a controlled substance, and federal law does not make possessing them a crime. Selling either for human use is selling an unapproved drug, and a "research use only" label does not change that when a shop markets it for people. Both are prohibited in sport under WADA's 2026 list (S2.2.4).

More from the desk

ALL ARTICLES →
THE ROUNDUP · MONTHLY

Receipts in your inbox. Once a month.

New audits, expired coupons pruned, lab notes from vials still on the bench. No marketing. No lifestyle copy. Unsubscribe in one click.

14,200 SUBSCRIBERS·0 SPONSORED ITEMS·11 ISSUES SINCE LAUNCH